4.3 Review

Therapeutic approaches against coronaviruses acute respiratory syndrome

Journal

PHARMACOLOGY RESEARCH & PERSPECTIVES
Volume 9, Issue 1, Pages -

Publisher

JOHN WILEY & SONS LTD
DOI: 10.1002/prp2.691

Keywords

antivirals; Coronaviruses; Covid-19; entry inhibitors; MERS; MERS-CoV; monoclonal antibodies; nucleoside analogues; plasma therapy; SARS; SARS-CoV; SARS-CoV-2

Funding

  1. project POR Calabria FESR/FSE 2014-2020

Ask authors/readers for more resources

Coronaviruses pose a global health threat and have caused several epidemics and one major pandemic in this century. While there are currently no approved treatments, FDA-approved and preclinical drugs have shown antiviral activity against coronaviruses. Current research has identified potential drugs that could impact the fight against these infections.
Coronaviruses represent global health threat. In this century, they have already caused two epidemics and one serious pandemic. Although, at present, there are no approved drugs and therapies for the treatment and prevention of human coronaviruses, several agents, FDA-approved, and preclinical, have shown in vitro and/or in vivo antiviral activity. An in-depth analysis of the current situation leads to the identification of several potential drugs that could have an impact on the fight against coronaviruses infections. In this review, we discuss the virology of human coronaviruses highlighting the main biological targets and summarize the current state-of-the-art of possible therapeutic options to inhibit coronaviruses infections. We mostly focus on FDA-approved and preclinical drugs targeting viral conserved elements.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available